Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The doses of elemental calcium and calcitriol in the first 6 months were significantly higher than those ones in the last 6 months [241 (188 to 244) vs. 135 (73 to 252) g; p<0.01 and 257 (192 to 381) vs. 34.3 (5.2 to 101) mcg, respectively; p = 0.001].

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

These patients were not different regarding baseline demographic, laboratory, coronary tomography or bone biopsy characteristics from those who completed the study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study

Study design awaiting verification · PLoS ONE · 2017

Original publication title

The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study

Fabiana Rodrigues Hernandes; Maria Eugênia Fernandes Canziani; Fellype Carvalho Barreto; Rodrigo Oliveira Santos; Valéria de Melo Moreira; Carlos Eduardo Rochitte; Aluizio Barbosa Carvalho

© 2017 Hernandes et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Parathyroidectomy (PTX) may cause low levels of PTH, leading to an excessive reduction of bone turnover, which is associated with poor outcomes in dialysis patients, including vascular calcification (VC). We aimed to prospectively investigate the impact of PTX on bone remodeling and its potential consequence on the progression of VC in hemodialysis patients. In this prospective study, 19 hemodialysis patients with severe secondary hyperparathyroidism (sHPT) were evaluated. All patients underwent laboratorial tests and coronary tomography at baseline and, 6 and 12 months after PTX; bone biopsy was performed at baseline and 12-month.

At baseline, all patients had increased PTH levels up to 2500 pg/mL and high turnover bone disease in their bone biopsies. Fourteen (74%) patients had VC. During the follow-up, there was a significant decrease of PTH at 6 and 12-month. At 12-month, 90% of the patients evolved to low turnover bone disease. During the period of the hungry bone syndrome (first 6 months), no change of coronary calcium score was observed. However, calcium score increased significantly thereafter (12th month).

There was an association between VC progression and the severity of low turnover bone disease. In conclusion, the shift from high to low turnover bone disease after PTX occurs in parallel to VC progression, contributing to the understanding of the complex pathophysiology involving mineral metabolism and cardiovascular disease in hemodialysis patients.

Authors’ abstract

Parathyroidectomy (PTX) may cause low levels of PTH, leading to an excessive reduction of bone turnover, which is associated with poor outcomes in dialysis patients, including vascular calcification (VC). We aimed to prospectively investigate the impact of PTX on bone remodeling and its potential consequence on the progression of VC in hemodialysis patients. In this prospective study, 19 hemodialysis patients with severe secondary hyperparathyroidism (sHPT) were evaluated. All patients underwent laboratorial tests and coronary tomography at baseline and, 6 and 12 months after PTX; bone biopsy was performed at baseline and 12-month.

At baseline, all patients had increased PTH levels up to 2500 pg/mL and high turnover bone disease in their bone biopsies. Fourteen (74%) patients had VC. During the follow-up, there was a significant decrease of PTH at 6 and 12-month. At 12-month, 90% of the patients evolved to low turnover bone disease. During the period of the hungry bone syndrome (first 6 months), no change of coronary calcium score was observed. However, calcium score increased significantly thereafter (12th month).

There was an association between VC progression and the severity of low turnover bone disease. In conclusion, the shift from high to low turnover bone disease after PTX occurs in parallel to VC progression, contributing to the understanding of the complex pathophysiology involving mineral metabolism and cardiovascular disease in hemodialysis patients.

Publication and source details

Original title: The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study

Fabiana Rodrigues Hernandes; Maria Eugênia Fernandes Canziani; Fellype Carvalho Barreto; Rodrigo Oliveira Santos; Valéria de Melo Moreira; Carlos Eduardo Rochitte; Aluizio Barbosa Carvalho

PLoS ONE · 2017

Competing Interests: FRH has received consulting and speaker fees from the following companies: Amgen, and Abbvie. MEFC has received consulting fees, speaker fees, or research grants from the following companies: Takeda, Amgen, Abbvie, Sanofi, Baxter, and Roche. FCB has received consulting fees, speaker fees, or research grants from the following companies: Amgen, and Sanofi. CER has received consulting and speaker fees from the following companies: Baldacci, Abbvie, Sanofi, and Lilly. ABC has received consulting fees, speaker fees, or research grants from the following companies: Amgen, Abbvie, Sanofi, and Lilly.

All other authors state that they have no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

  • Conceptualization: FRH MEFC FCB ABC.

  • Data curation: FRH FCB.

  • Formal analysis: FRH MEFC ABC.

  • Funding acquisition: FRH.

  • Investigation: FRH.

  • Methodology: FRH MEFC FCB ROS VMM CER ABC.

  • Project administration: ABC.

  • Resources: FRH MEFC ABC.

  • Supervision: FRH MEFC ABC.

  • Validation: FRH FCB VMM CER.

  • Visualization: FRH MEFC ABC.

  • Writing: original draft: FRH MEFC ABC.

  • Writing: review & editing: FRH MEFC ABC.

* E-mail: aluizio@uol.com.br
© 2017 Hernandes et al2017Hernandes et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.National Counsel of Technological and Scientific Development (CNPq)Hernandes Fabiana Rodrigues The first author (FRH) received financial support: National Counsel of Technological and Scientific Development (CNPq).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T19:43:57.672840+00:00

DOI: 10.1371/journal.pone.0174811 · PMC5383047